[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.173.45. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
August 1, 2017

Treatment of Cholesterol in 2017

Author Affiliations
  • 1Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine
  • 2The Center for Outcomes Research and Evaluation, Yale–New Haven Health, New Haven, Connecticut
JAMA. 2017;318(5):417-418. doi:10.1001/jama.2017.6753

Clinicians and patients may find recent studies relevant to decisions about lipid-lowering therapy to be perplexing. There are now, for the first time, 3 evidence-based options to modify atherosclerotic cardiovascular disease risk via lipid-lowering medications. With new information emerging, recent guidelines aging, and decisions needing to be made, this is an opportune time to review lipid-lowering therapy in the age of increasing evidence-based choice. The focus in this Viewpoint is on typical patients, not those with extreme phenotypes.

×